07:00 , Mar 25, 2010 |  BC Innovations  |  Targets & Mechanisms

SK channel activation for alcoholism

Researchers at the Ernest Gallo Clinic and Research Center at University of California, San Francisco have found that activating small conductance calcium-activated potassium channels in the nucleus accumbens region of the brain could help treat...
08:00 , Jan 9, 2006 |  BioCentury  |  Finance

Post-launch report

Post-launch report...
07:00 , Apr 25, 2005 |  BC Week In Review  |  Clinical News

Acamprosate calcium neurology data

A pooled analysis from five 1-year, double-blind, placebo-controlled trials in 1,681 patients showed that the overall incidence of spontaneously reported adverse events was similar between the 1,998 mg daily Campral arm and the placebo arm....
07:00 , Apr 25, 2005 |  BC Week In Review  |  Clinical News

Acamprosate calcium: Post-marketing study data

A pooled analysis of various studies in 3,395 subjects showed that the incidence of adverse events in patients treated with Campral concomitantly with medications such as antidepressants, anxiolytics, sedatives, hypnotics and analgesics were comparable to...
08:00 , Jan 17, 2005 |  BC Week In Review  |  Company News

Forest Laboratories sales and marketing update

FRX launched its Campral acamprosate delayed-released tablets to treat alcohol dependence in patients who are abstinent from alcohol at treatment initiation. Campral is partnered with Merck KGaA (FSE:MRK, Darmstadt, Germany) and received FDA approval in...
08:00 , Jan 11, 2005 |  BC Extra  |  Company News

Forest launches Campral

FRX launched its Campral acamprosate delayed-released tablets to treat alcohol dependence in patients who are abstinent from alcohol at treatment initiation. Campral is partnered with Merck KGaA (FSE:MRK) and received FDA approval in July 2004....
08:00 , Jan 10, 2005 |  BioCentury  |  Finance

New product sales to watch

New product sales to watch...
08:00 , Dec 20, 2004 |  BioCentury  |  Strategy

Alkermes: Looking to break out

While drug delivery has often been portrayed as an easy route to company-building, in general the promise has exceeded the reality. Alkermes Inc. believes it will be an exception, which will be witnessed by its...
07:00 , Oct 18, 2004 |  BC Extra  |  Financial News

Forest beats Street

FRX posted fiscal second quarter EPS of $0.79, beating the Street by $0.03 and up 61% up from $0.49 in the same quarter last year. Before FRX pre-announced strong earnings earlier this month, the Street...
07:00 , Oct 4, 2004 |  BioCentury  |  Finance

3Q approvals/3Q setbacks

3Q approvals/3Q setbacks...